8 Reduction in estimated 10-years cardiovascular disease risk in dyslipidaemic hypertensive subjects in monotherapy with ACE-inhibitors (ACE-Is) or Calcium Channel Blockers (CCBs) by the use of a combined nutraceutical

2010 ◽  
Vol 5 (1) ◽  
pp. 6
Author(s):  
A.F.G. Cicero ◽  
B. Gerocarni ◽  
I. Setnikar ◽  
C. Benvenuti ◽  
L. Rovati
Hypertension ◽  
2021 ◽  
Vol 77 (2) ◽  
pp. 328-337
Author(s):  
Chien-Chang Lee ◽  
Meng-tse Gabriel Lee ◽  
Wan-Ting Hsu ◽  
James Yeongjun Park ◽  
Lorenzo Porta ◽  
...  

Calcium channel blockers (CCBs) are known to reduce the availability of iron—an important mineral for intracellular pathogens. Nonetheless, whether the use of CCBs modifies the risk of active tuberculosis in the clinical setting remains unclear. To determine whether CCBs may modify the risk of active tuberculosis disease, we conducted a nested case-control study using the National Health Insurance Research Database of Taiwan between January 1999 and December 2011. Conditional logistic regression and disease risk score adjustment were used to calculate the risk of active tuberculosis disease associated with CCB use. Subgroup analyses investigated the effect of different types of CCBs and potential effect modification in different subpopulations. A total of 8164 new active tuberculosis cases and 816 400 controls were examined. Use of CCBs was associated with a 32% decrease in the risk of active tuberculosis (relative risk [RR], 0.68 [95% CI, 0.58–0.78]) after adjustment with disease risk score. Compared with nonuse of CCBs, the use of dihydropyridine CCBs was associated with a lower risk of tuberculosis (RR, 0.63 [95% CI, 0.53–0.79]) than nondihydropyridine CCBs (RR, 0.73 [95% CI, 0.57–0.94]). In contrast, use of β-blockers (RR, 0.99 [95% CI, 0.83–1.12]) or loop diuretics (RR, 0.88 [95% CI, 0.62–1.26]) was not associated with lower risk of tuberculosis. In subgroup analyses, the risk of tuberculosis associated with the use of CCBs was similar among patients with heart failure or cerebrovascular diseases. Our study confirms that use of dihydropyridine CCBs decreases the risk of active tuberculosis.


2019 ◽  
Vol 30 (1) ◽  
pp. 101-106 ◽  
Author(s):  
Christopher Jantzen ◽  
Christian M Madsen ◽  
Bo Abrahamsen ◽  
Susanne Van Der Mark ◽  
Benn R Duus ◽  
...  

Purpose: To evaluate the predictive value of pre-fracture medication usage on 30-day mortality following a hip fracture. Methods: Information on age, sex, fracture type, time of death and Charlson co-morbidity index (CCI) was collected from the Danish National Patient Registry on all patients above 60 years, sustaining a hip fracture during the period January 1995 to December 2013. Information on drug usage was obtained from the Danish National Prescription Database. Hazard ratios were calculated with 30-day mortality as the outcome. A univariate and 3 multivariate analyses were conducted with increasing adjustments, starting with age, sex and fracture type, adding co-morbidity and dose in the latter. Results: 141,201 patients were included and a total of 12 drugs/drug groups were identified for analysis. Increased mortality was evident in all analyses for antiarrhythmics, beta blockers, proton pump inhibitors, loop diuretics, opioids, acetaminophen and for psycholeptics. For ACE-inhibitors, increased mortality was found in all analyses, except after adjustment for co-morbidity and dose. For thiazide diuretics, a significantly reduced mortality was evident in all but the univariate analyses while NSAIDs and statins were associated with a significantly reduced mortality in all analyses. For calcium channel blockers, an insignificant decrease was found after adjustment for dose. Further analysis showed a dose-response relationship for all drugs except ACE-inhibitors and calcium channel blockers. Conclusion: The study shows a correlation between pre-fracture usage of certain drugs and 30 day mortality after a hip fracture.


Open Medicine ◽  
2008 ◽  
Vol 3 (3) ◽  
pp. 287-293
Author(s):  
Zorica Jovic ◽  
Vidojko Djordjevic ◽  
Karin Vasic ◽  
Snezana Cekic ◽  
Jankovic Irena

AbstractArterial hypertension and proteinuria are important factors associated with the progression of both diabetic and nondiabetic chronic kidney disease. The objective of the present study was to determine the influence of different antihypertensive drug groups on urinary albumin excretion (UAE) as related to blood pressure in non-diabetic population. Subjects (n=39) with chronic renal disease accompanied by mild to moderate hypertension and varying degrees of proteinuria were divided into 3 groups based on UAE values and placed on nonpharmacological and/or treatment with an antihypertensive drug regimen (consisting of one or more antihypertensive drugs [beta blocker, ACE inhibitor or calcium-channel blocker]) to achieve a target blood pressure ≤ 130/85 mmHg. Periodic UAE measurements were performed. A reduction was observed over time in most patients, however, it reached statistical significance only in the microalbuminuric group (P<0.01). Patients were further stratified into 5 groups depending on assigned therapy: 0, nonpharmacological treatment; 1-drug group 1; 12-drug groups 1 and 2; 13-drug groups 1 and 3; 123-all 3 drug groups (1-ACE inhibitors, 2-beta blockers, 3-calcium channel blockers). A statistically significant change in mean UAE values at the start and end of the study period in patients assigned to drug groups 12, 13, and 123 was achieved (P < 0.05). Also, there was a statistically significant difference in the average reduction of proteinuria under varying antihypertensive drug regimens (P < 0.05). In conclusion, in patients with hypertension, changes in UAE depend on initial UAE values and administered antihypertensive treatment. ACE inhibitors combined with calcium channel blockers resulted in a higher UAE reduction than other drug groups.


2002 ◽  
Vol 62 ◽  
pp. S53-S60 ◽  
Author(s):  
Francesco Locatelli ◽  
Lucia Del Vecchio ◽  
Simeone Andrulli ◽  
Sara Colzani

Author(s):  
N. V. Ivanov

The aim of the study was to evaluate the impact of antihypertensive therapy with slow calcium-channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and ß-adrenergic receptor blockers on the metabolism and blood levels of major adrenal androgens and gonads, as well as the insulin resistance in males with arterial hypertension (AH) Ninety-one patients with AH and 15 age-matched healthy male controls were examined The hypertensive males treated with slow calcium-channel blockers or ACE inhibitors were found to have a lower level of insulin and higher levels of dehydroepiandrosterone sulfate and free testosterone on the 30th day of treatment Those on blockers were observed to have a higher level of insulin and lower levels of major adrenal and testicular androgens as compared with their baseline levels Therapy did not alter the levels of gonadotropic hormones, estradiol, and cortisol and they did not differ in the compared groups The family history of AH has a modulating effect on a hormonal response in males with AH treated with antihypertensive agents


Sign in / Sign up

Export Citation Format

Share Document